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Albany, NY; Torrance, Calif; Boca Raton, Fla; and Maywood, Ill
Objective: We report the 5-year outcomes of thoracic endovascular aneurysm repair (TEVAR) using the Medtronic
Vascular Talent Thoracic Stent Graft System (Medtronic Vascular, Santa Rosa, Calif) in patients considered low or
moderate risk for open surgical repair.
Methods: The Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic
Aortic Aneurysms (VALOR) trial was a prospective, nonrandomized, multicenter, pivotal study conducted at 38 U.S.
sites. Between December 2003 and June 2005, VALOR enrolled 195 patients who were low or moderate risk (0, 1, and
2) per the modified Society for Vascular Surgery and American Association for Vascular Surgery criteria. The patients had
fusiform thoracic aortic aneurysms (TAAs) and/or focal saccular TAAs/penetrating atherosclerotic ulcers. Standard
follow-up interval examinations were conducted at 1 month, 6 months, 1 year, and annually thereafter.
Results:Over the 5-year follow-up, 76 deaths occurred (43.9%). Freedom from all-cause mortality was 83.9% at 1 year and
58.5% at 5 years. Most deaths were due to cardiac, pulmonary or cancer-related causes. Freedom from aneurysm-related
mortality (ARM) was 96.9% at 1 year and 96.1% at 5 years. There was only 1 case of ARM after the first year of follow-up.
Over the 5-year follow-up period, four patients were converted to open surgery and four patients experienced aneurysm
rupture. The 5-year freedom from aneurysm rupture was 97.1% and the 5-year freedom from conversion to surgery was
97.1%. The incidence of stent graft migration (>10mm) was<1.8% in each year of follow-up. The rate of type I endoleak
was 4.6% at 1 month, 6.3% from 1 month to 1 year, and 3.8% during year 5. The rate of type III endoleak was 1.3% at
1 month, 1.9% from 1 month to 1 year, and 1.9% during year 5. Through 5 years, 28 patients (14.4%) underwent 31
additional endovascular procedures on the original target lesion. The 5-year freedom from secondary endovascular
procedures was 81.5%.
Conclusions:Through 5-year follow-up in patients who were candidates for open surgical repair, TEVAR using the Talent
Thoracic Stent Graft System has demonstrated sustained protection from ARM, aneurysm rupture, and conversion to
surgery, and durable stent graft performance. Close patient follow-up remains essential after TEVAR. (J Vasc Surg
2012;56:1214-21.)
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cOpen surgical repair of thoracic aortic aneurysms
(TAAs), even at centers of excellence, carries with it a
significant risk of morbidity and mortality.1-4 Early data
from thoracic stent graft trials established thoracic endovas-
cular aneurysm repair (TEVAR) as a safe and effective
strategy for treating TAAs.5-8 Data from nonrandomized
clinical trials have demonstrated lower perioperative mor-
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1214idity and mortality with TEVAR compared with open
epair.5,9-11 Thoracic endograft technology continues to
volve and yet there are only limited data available from
rospective multi-institutional trials regarding long-term
ollow-up with TEVAR. Here we report the 5-year out-
omes from The Evaluation of the Medtronic Vascular
alent Thoracic Stent Graft System for the Treatment of
horacic Aortic Aneurysms (VALOR) trial using the
edtronic Vascular Talent Thoracic Stent Graft System
Medtronic Vascular, Santa Rosa, Calif).
ETHODS
Detailed descriptions of the VALOR trial design and
he Talent Thoracic Stent Graft System have been reported
reviously.5 Briefly, VALOR was a prospective, nonran-
omized clinical trial of the Talent Thoracic Stent Graft
ystem conducted at 38 U.S. sites, with enrollment occur-
ing between December 2003 and June 2005. The pivotal
est group, described here, consisted of 195 patients
VALOR also included high-risk and registry cohorts).
Follow-up protocol. At 1, 6, and 12 months, and
nnually thereafter, standard follow-up evaluations in-
luded physical examination, chest X-rays, and computed
omography (CT) scan or magnetic resonance angiogra-
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Volume 56, Number 5 Foley et al 1215phy. Imaging obtained through 1 year was evaluated by a
core reference laboratory (M2S, Lebanon, NH).
Endoleaks were defined according to the type I to IV
nomenclature.12 Migration was defined as 10 mm prox-
imal or distal movement of the stent graft relative to fixed
anatomic landmarks. Aneurysm expansion was defined as
an increase in diameter 5 mm between the 1-month and
subsequent follow-up visits. Major adverse events (MAEs)
were defined as death due to the procedure, any death
within 30 days of the procedure, respiratory complications,
renal insufficiency or failure, cardiac events, neurologic
events, aneurysm rupture, bowel ischemia, major bleeding,
or vascular complications. An MAE that was identified as a
serious adverse event by the clinical investigator was de-
fined as a serious MAE. All deaths and aneurysm ruptures
through 5 years were adjudicated by an independent phy-
sician advisory group managed by Harvard Clinical Re-
search Institute (Boston, Mass). All MAEs within 1 year,
including deaths and ruptures, were adjudicated by the
same group. After 1 year, potential MAEs were not adjudi-
cated by an independent body; consequently, in this report,
we provide an update on all serious adverse events as
defined by the investigators.
Aneurysm-related death was defined as any death oc-
curring within 30 days of the procedure or at any point as a
consequence of aneurysm rupture, conversion to open
surgery, or any other secondary endovascular procedure
relative to the treated TAA as evidenced by CT scan,
angiography, or direct observation at surgery or autopsy.
All statistical analyses were performed with SAS v. 9.1
(SAS Institute, Cary, NC). For continuous variables, the
mean and standard deviation are provided; P values were
calculated using standard t-tests. Kaplan-Meier curves
were used to plot freedom from event over time. Cox
proportional-hazard regressions were performed to identify
potential risk factors.
RESULTS
Baseline patient characteristics and procedure data have
been published previously.5 Talent thoracic stent grafts
were successfully deployed in 194 of the 195 patients
enrolled in the VALOR test group (99.5%). Access failure
prevented one patient from successfully undergoing
TEVAR. Over the 5-year follow-up period, 76 patients
died, 14 withdrew from the trial, and eight were lost to
follow-up. A total of 96 patients had 5-year follow-up
information available for analysis.
Mortality. There were 76 deaths (76/173, 43.9%) in
the VALOR test arm over the 5-year follow-up period
(Table I). The Kaplan-Meier estimate for freedom from
all-causemortality at 1 year and 5 years was 83.9% (standard
error [SE]  2.6%) and 58.5% (SE  3.7%), respectively
(Fig 1). Multivariate analysis revealed that a history of
cerebrovascular accident (hazard ratio [HR], 2.3; 95% con-
fidence interval [CI], 1.2-4.3) and a history of chronic
obstructive pulmonary disorder (COPD) (HR, 1.9; 95%
CI, 1.2-3.0) were associated with increased all-cause mor-
tality during the 5-year follow-up period (Table II). TSeven patients died of an aneurysm-related cause
hrough 5 years (Table I). Estimated freedom from
neurysm-related mortality (ARM) at 1 year and 5 years was
6.9% (SE 1.3%) and 96.1% (SE 1.4%), respectively (Fig
). Six of the aneurysm-related deaths (86%) occurred within
he first year after TEVAR (four of these were within 30 days
f the procedure) and one occurred during the third year. The
our deaths 30 days were due to atheroembolic multisys-
em failure, stroke, periprocedural cardiac arrest, and sepsis.
he two additional deaths within the first year were due to
retrograde type A dissection and an aneurysm rupture.
he single aneurysm-related death after 1 year was due to a
ate aneurysm rupture. None of the seven patients whose
eaths were aneurysm-related had a secondary procedure.
Aneurysm rupture. There were a total of four aneu-
ysm ruptures over the 5-year follow-up period (mean, 27.3
onths; range, 8-49 months). The Kaplan-Meier estimate
f survival free from aneurysm rupture through 5 years was
7.1% (SE 1.5%) (Fig 3). Two ruptures resulted in death.
here was one rupture in the first year of follow-up, two in
he third year, and one in the fifth year. The first patient
pent 7months in the hospital following TEVAR secondary
o multiple postoperative complications. At autopsy, a rup-
ure was discovered at the distal end of the thoracic stent.
able I. Cause of death within 5 years for VALOR
est-group patients
Aneurysm-related deaths
Strokea 1
Cardiac arrest/MIa 1
Ruptured TAA 2
TAA dissection 1
Renal failurea 1
Sepsisa 1
All-cause mortality
Cardiac arrest/MI 13
Respiratory failure 8
Cancer 7
Congestive heart failure 4
Hemorrhagic stroke 4
Multiorgan failure 4
Renal failure 4
COPD 3
Bowel ischemia 2
Ruptured AAA 2
Sepsis 2
Aortic infection 1
Acute morphine poisoning 1
Cirrhosis 1
Embolic stroke (30 days) 1
Gastrointestinal bleed 1
Hemoptysis 1
Natural causes 1
Peripheral vascular disease 1
Unknown 8
Total deaths, 5 years 76
AA, Abdominal aortic aneurysm, COPD, chronic obstructive pulmonary
isease;MI,myocardial infarction; TAA, thoracic aortic aneurysm;VALOR,
ascular Talent Thoracic Stent Graft System for the Treatment of Thoracic
ortic Aneurysms.
Death within 30 days.his patient had both 1-month and 6-month CT scans in
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November 20121216 Foley et althe hospital, and each revealed no evidence of endoleak,
migration, or device failure. Imaging core laboratory review
of the patient’s preoperative and 1-month imaging demon-
strated that this patient had a thoracoabdominal aneurysm
and should have been excluded from the trial. The second
patient ruptured approximately 25 months following
TEVAR and suffered a cardiac arrest on transfer to the
enrolling facility. At autopsy this patient was noted to have
a “gap” between the proximal and distal stent, consistent
with a type III endoleak. This patient missed both 12- and
24-month follow-up visits and did not have any follow-up
imaging during this interval. A 6-month CT scan did not
demonstrate an endoleak. The third patient ruptured ap-
proximately 27 months after TEVAR and was successfully
managed with the endovascular placement of a cuff. The
fourth patient ruptured nearly 49 months after TEVAR in
the setting of a transverse arch aneurysm and expanding
descending TAA with a known proximal type I endoleak.
This patient underwent successful hybrid repair consisting
of a transverse arch repair and relining of the prior thoracic
stent graft repair.
Conversion to surgery. Four patients were converted
to open surgery over the 5-year follow-up period. The first
Fig 1. Kaplan-Meier plot of freedom from all-cause mortality for
the Vascular Talent Thoracic Stent Graft System for the Treatment
of Thoracic Aortic Aneurysms (VALOR) test-group patients. CI,
Confidence interval; SE, standard error.patient was converted to open repair approximately 9 ionths after TEVAR for complications related to an infec-
ion in the stented segment of the aorta. This patient died
ear the end of the second year of follow-up due to hemop-
ysis. A second surgical conversion occurred approximately
6 months after TEVAR in a patient with aneurysmal
xpansion of the distal thoracic aorta, contiguous with the
riginal aneurysm. There was no endoleak reported on
ither the 6- or 12-month CT scan. Core laboratory review
f the preoperative CT demonstrated an inadequate distal
anding and this patient should have been excluded from
he trial. This patient was alive at 5-year follow-up. A third
onversion occurred early in the third year, approximately
5months after TEVAR, in a patient with aneurysm expan-
ion due to a persistent type I endoleak after failure of a
econdary endovascular procedure. This patient underwent
artial conversion (proximal Dacron graft was sewn to the
reviously placed Talent stent graft distally) and was alive at
-year follow-up despite having evidence of continued
neurysm growth. The fourth open conversion occurred
pproximately 49 months after device implantation in a
atient who had a type I endoleak leading to aneurysm
xpansion and rupture. This patient was exited from the
rial 30 days after open conversion. The Kaplan-Meier
stimate of 5-year conversion-free survival was 97.1% (SE
.4%) (Fig 4).
Predictors of a composite end point consisting of com-
ined ARM, conversions, and ruptures are listed in Table
I. Unresolved endoleaks at the conclusion of the proce-
ure (HR, 6.3; 95% CI, 1.2-32.3) and a history of periph-
ral vascular disease (HR, 5.9; 95% CI, 1.7-20.3) were
redictive of the composite end point.
Endoleak. The occurrence of endoleaks through 5
ears of follow-up is summarized in Table III. There were
2 site-reported type I endoleaks (19 proximal, 13 distal)
ocumented over the 5-year follow-up period. Nine pa-
ients were reported to have persistent type I endoleaks
noted over at least two follow-up evaluations). Four of
hose patients (44%) had an associated increase in aneurysm
iameter (5 mm). Two of these patients went on to
onvert to open surgical repair (one patient ruptured).
our of the nine patients with persistent type I endoleaks
ied over the follow-up period; three deaths were from
auses unrelated to the aneurysm, and one was from un-
nown causes. Two of the four patients that died had
nresolved type I endoleaks. There were 49 site-reported
ccurrences of type II endoleaks. Eleven type III endoleaks
ere reported over the 5-year follow-up. All of these pa-
ients had junctional endoleaks; none had any kinking,
wisting, fracture, or other loss of device integrity.
Migration and device integrity. Site-reported stent
raft migration was noted in 0.6% in the first year, 1.8% in
he second year, 1% in the third year, 1.2% in the fourth
ear, and 1.3% in the fifth year (Table III). There were eight
bservations of loss of stent graft integrity, all of which
ccurred after 24-month follow-up. There were six reports
f stent graft kinking in the first year after initial device
mplantation and an additional nine reports out to 5-year
F
t
o
For every additional mm.
bFor every additional cc.
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Volume 56, Number 5 Foley et al 1217Fig 2. Kaplan-Meier plot of freedom from aneurysm-related
mortality (ARM) for the Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms
(VALOR) test-group patients. CI, Confidence interval; SE,
standard error. Cig 3. Kaplan-Meier plot of freedom from aneurysm rupture for
he Vascular Talent Thoracic Stent Graft System for the Treatment
f Thoracic Aortic Aneurysms (VALOR) test-group patients.Table II. Results of Cox proportional-hazard regression analysis on selected events within 5 years for VALOR test-
group patients
Baseline factor Hazard ratio 95% CI P value
Predictors of ARM, conversion to surgery, and rupture
Endoleaks observed immediately after procedure 6.3 1.2-32.3 .030
Peripheral vascular disease 5.9 1.7-20.3 .005
Predictors of reinterventions within 5 years
Maximum aneurysm diametera 1.070 1.032-1.110 .001
Aneurysm lengtha 1.006 1.001-1.011 .020
Predictors of all-cause mortality within 5 years
Cerebrovascular accident 2.3 1.2-4.3 .010
COPD 1.9 1.2-3.0 .006
Predictors of major adverse events within 5 years
Aortic tortuosity 15.9 4.4-57.7 .001
Carotid artery disease 4.2 2.0-8.8 .001
COPD 1.8 1.2-2.6 .003
Blood loss 200 mLb 1.7 1.2-2.4 .006
Tortuosity of access artery (moderate or severe) 1.7 1.1-2.6 .020
Implantation in zones 1 or 2 1.6 1.1-2.3 .020
Predictors of paraplegia and paraparesis within 5 years
COPD 3.9 1.3-11.6 .010
Distal neck lengtha 0.2 0.1-0.7 .010
ARM, Aneurysm-related mortality; CI, confidence interval; COPD, chronic obstructive pulmonary disease; VALOR, Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms.
aI, Confidence interval; SE, standard error.
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November 20121218 Foley et alfollow-up. There were no reports of loss of device patency
over the 5-year follow-up period.
Additional endovascular procedures. Twenty-eight
patients (14.4%, 28/194) underwent 31 additional endo-
vascular procedures on the original aneurysm over the
5-year follow-up period. Kaplan-Meier estimated freedom
from secondary endovascular procedures was 81.5% (SE 
3.3%) (Fig 5). Three patients each had two secondary
procedures during that time. After 1 year of follow-up, 14
patients underwent 15 additional endovascular procedures
on the original aneurysm. Thirteen (87%) of these were
performed to resolve endoleaks (one patient also had
concomitant device migration), and two were performed
for aneurysm expansion. Two patients each had two
secondary procedures after 1 year of follow-up, both to
treat persistent endoleak. In addition to the 31 addi-
tional endovascular procedures performed on the origi-
nal aneurysm over the 5-year follow-up period, there
were two performed for a second thoracic aneurysm (one
was ruptured), and one was performed to treat an ab-
dominal aortic aneurysm. Cox regression analysis identi-
fied maximum aneurysm diameter (HR, 1.007 for each
additional mm; 95% CI, 1.032-1.110) and aneurysm
Fig 4. Kaplan-Meier plot of freedom from conversion to surgery
for the Vascular Talent Thoracic Stent Graft System for the Treat-
ment of Thoracic Aortic Aneurysms (VALOR) test-group pat-
ients. CI, Confidence interval; SE, standard error.length at diagnosis (HR, 1.006 for each additional mm; f5% CI, 1.001-1.011) as predictors of additional endo-
ascular procedures over the 5-year follow-up.
Changes in aneurysm diameter. Between 1 month
nd 5 years of follow-up, aneurysm sac diameter had de-
reased (5 mm) or remained unchanged in 84.6% (Table
V). Increased aneurysm sac diameter (by 5 mm) was
oted in 15.4% over the same time period. There were 48
eparate observations of aneurysm sac expansion occurring
n 27 patients. Seven of these patients underwent additional
ndovascular procedures, all of which were successful. One
atient with documented sac expansion in the descending
horacic aorta and distal arch ruptured, resulting in an open
onversion and hybrid stent graft repair. Another eight
atients died over the follow-up period with none of the
eaths being adjudicated as aneurysm-related.
Major adverse events. The relative distribution of
AEs occurring from 31 days through 5 years was cardiac
omplications in 29.8% of patients (57/191), pulmonary
omplications in 17.3% of patients (33/191), renal com-
lications in 11.5% of patients (22/191), vascular compli-
ations in 11% of patients (21/191), and neurologic events
n 7.9% of patients (15/191). Predictors of MAEs from
ndex procedure through 5-year follow-up are listed in
able II. Patients with aortic tortuosity, defined as the ratio
f the centerline length to straight line lengths between the
ubclavian and celiac arteries (HR, 15.9; 95% CI, 4.4-
7.7), history of carotid artery disease (HR, 4.2; 95% CI,
.0-8.8), history of COPD (HR, 1.8; 95% CI, 1.2-2.6),
lood loss during procedure of more than 200 mL (HR,
.7; 95% CI, 1.2-2.4), moderate or severe tortuosity of the
ccess vessel as assessed by the investigational site (HR, 1.7;
5% CI, 1.1-2.6), and implantation in zone 1 or 2 (HR,
.6; 95% CI, 1.1-2.3), had a higher risk of experiencing an
AE within 5 years.
Neurologic complications. There were 23 strokes
hat occurred in 21 patients over the 5-year follow-up
eriod (10.7%, 21/195). Eight of these events (seven
atients) occurred within the first 30 days (3.6%, 7/195),
nd all were embolic in origin. Two of these events in the
rst 30 days after the stent graft implant were fatal, and the
eath of a third patient within 30 days was attributed to
cute myocardial infarction and a cerebral infarct. None of
hese three patients had a history of stroke. Beyond 1 year,
here were six strokes, three of them fatal. Three of the six
trokes were embolic in origin, and the other three were
emorrhagic. The Kaplan-Meier 5-year estimate of free-
om from stroke was 88.2% (SE  6.0%).
Seventeen patients experienced spinal cord ischemia
SCI) within 30 days after TEVAR (8.7%, 17/195). Three
f these patients had paraplegia (1.5%, 3/195), and 14
atients had paraparesis (7.2%, 14/195). There were two
ases of SCI after 30 days (1%, 2/195). One patient expe-
ienced paraplegia at 32 days post-TEVAR, and an addi-
ional case of paraparesis occurred 2 days following a pa-
ient’s open repair of an aortic dissection that had been
iscovered at the 1-month imaging examination. Eight
atients had resolution of paraparesis at 1-year or the last
ollow-up visit, but there was no resolution in the four cases
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Volume 56, Number 5 Foley et al 1219of paraplegia prior to the end of the study period or death of
the patient. Predictors of SCI included a history of COPD
(HR, 3.9; 95% CI, 1.3-11.6) and a shorter distal nonaneu-
rysmal neck length (HR, 0.02; 95% CI, 0.1-0.7). The
Kaplan-Meier 5-year estimate of freedom from SCI was
Table III. Site-reported endoleak and migration for VALO
Device-related event
Through 1-
month visita
1- to 12-month
visita
1
mo
Endoleak 16.4% (25/152) 17.7% (28/158) 12.0%
Type I 4.6% (7/152) 6.3% (10/158) 3.7%
Type Ia (proximal) 2.6% (4/152) 3.2% (5/158) 2.8%
Type Ib (distal) 2.0% (3/152) 3.2% (5/158) 0.9%
Type II 7.2% (11/152) 9.5% (15/158) 7.4%
Type III 1.3% (2/152) 1.9% (3/158) 1.9%
Type IV 0.7% (1/152) 0.0% (0/158) 0.0%
Unknown 3.9% (6/152) 1.9% (3/158) 0.9%
Migration 10 mm
from 1 mo 0.6% (1/163) 1.8%
VALOR, Vascular Talent Thoracic Stent Graft System for the Treatment of
aCore laboratory reported.
bSite reported.
Fig 5. Kaplan-Meier plot of freedom from secondary procedures
for the Vascular Talent Thoracic Stent Graft System for the Treat-
ment of Thoracic Aortic Aneurysms (VALOR) test-group pat-
ients. CI, Confidence interval; SE, standard error.92.3% (SE  4.8%). dAortic dissection. Three of the 194 patients (1.5%)
eveloped a retrograde type A dissection during the
ollow-up period. Two of these patients were diagnosed
n routine 1-month follow-up imaging. One of these pa-
ients underwent open repair and died postoperatively
econdary to respiratory failure after a protracted course.
he other patient was observed due to significant medical
omorbidities and expired approximately 3 months after
EVAR. The third patientwas diagnosed 7months following
EVAR after undergoing imaging for chest pain. This patient
nderwent open repair and died of an unknown cause at 32
onths. There were no aortic dissections observed after this
ime, through the end of the study period.
ISCUSSION
Early data from multicenter reports confirmed the
afety and efficacy of TEVAR and improved outcomes
ompared with open repair.5,8,10,11,13 The VALOR test
rm presented here was used as the pivotal data set to
upport Food and Drug Administration approval of the
alent Thoracic Stent Graft in 2008. The 5-year follow-up
est-group patients
24-
sitb
24- to 36-
month visitb
36- to 48-month
visitb
48- to 60-month
visitb
108) 14.7% (15/102) 11.3% (9/80) 10.8% (8/74)
08) 5.9% (6/102) 3.8% (3/80) 2.7% (2/74)
08) 2.9% (3/102) 3.8% (3/80) 1.4% (1/74)
08) 2.9% (3/102) 0.0% (0/80) 1.4% (1/74)
08) 5.9% (6/102) 6.3% (5/80) 5.4% (4/74)
08) 2.0% (2/102) 0.0% (0/80) 2.7% (2/74)
08) 0.0% (0/102) 0.0% (0/80) 0.0% (0/74)
08) 1.0% (1/102) 2.5% (2/80) 0.0% (0/74)
13) 1.0% (1/104) 1.2% (1/85) 1.3% (1/77)
acic Aortic Aneurysms.
able IV. Site-reported changes to aneurysm diameter
uring follow-up for VALOR test-group patients
ollow-up
nterval Increase 5 mm
No change 5
mm Decrease 5 mm
-6
months
7.9% (7/89) 66.3% (59/89) 25.8% (23/89)
-12
months
7.0% (6/86) 55.8% (48/86) 37.2% (32/86)
-24
months
8.7% (8/92) 48.9% (45/92) 42.4% (39/92)
-36
months
8.3% (7/84) 46.4% (39/84) 45.2% (38/84)
-48
months
13.9% (10/72) 37.5% (27/72) 48.6% (35/72)
-60
months
15.4% (10/65) 35.4% (23/65) 49.2% (32/65)
ALOR, Vascular Talent Thoracic Stent Graft System for the Treatment of
horacic Aortic Aneurysms.R t
2- to
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November 20121220 Foley et alliterature from prospective multicenter TEVAR trials re-
porting on long-term outcomes.9
There were 76 deaths over the 5-year follow-up period,
seven of which were aneurysm-related. Survival decreased
steadily over the follow-up period with an estimated free-
dom from all-cause mortality of 58.5% at 5 years. Most
deaths over the 5-year follow-up period were from cardiac,
pulmonary, or cancer-related causes, leading to an esti-
mated freedom from ARM of 96.1%. The majority of
aneurysm-related deaths (4 of 6) occurred in the first 30
days after device implantation and only one occurred after
the first year. The low rate of late ARM coupled with
steadily decreasing survival over the length of the trial
highlights the efficacy of TEVAR over the follow-up period
but also speaks to the fragility of aneurysm patients in the
post-TEVAR period. Similar findings have been reported in
the literature.14 Makaroun and colleagues reported an
overall survival rate of 68% in the multi-institutional Gore
TAG phase II trial (W. L. Gore, Inc, Flagstaff, Ariz).9 The
majority of deaths in that trial were attributed to cardiopul-
monary, cerebrovascular, or cancer-related events. Only
four aneurysm-related deaths were recorded in the TEVAR
group of the Gore trial and all occurred in the first 3months
(compared with 11 in the open surgical group). Fattori and
colleagues reported on outcomes of over 400 patients
treated with the Talent Thoracic Stent Graft for a variety of
aortic problems using retrospective registry data from seven
European centers.15 Kaplan-Meier estimated 5-year sur-
vival was 74.1%, and freedom from aneurysm-related death
was 90.2% at 5 years. A number of single-center experiences
have also been reported. Stone and colleagues reported
4-year survival estimates of 60%  8% for degenerative
aneurysms that were fit for open repair and treated with
TEVAR using a variety of different devices.16 Czerny and
colleagues published results on 113 TEVAR procedures
performed for descending thoracic aneurysms with a mean
follow-up of 54 months.17 Kaplan-Meier survival estimates
at 5 and 10 years were 60% and 42%, respectively. Five-year
and 10-year aorta-related survival estimates were 90% and
83%, respectively. Single-institution data from high-risk
patients treated with the Cook TX1 and TX2 devices (Cook
Medical, Inc, Bloomington, Ind) demonstrated overall sur-
vival of 70% at 5 years, with ARM of 10%.18 Lee and
colleagues recently provided sobering data on the long-
term outcomes of 400 TEVAR procedures at a single
institution performed for various indications.19 Estimated
survival at 48months was 53% 4.3%, withmost explained
deaths related to cardiac, pulmonary, or cerebrovascular
events. When evaluated collectively, these data lend further
support to the observation that in the post-TEVAR period
the majority of patients are succumbing to their underlying
comorbidities and not from aneurysm-related causes.
We observed a 15.4% rate of sac expansion over the
5-year follow-up period. An appropriate benchmark for this
value is uncertain given the lack of long-term multicenter
data. One important limitation of these data is that after 1
year only 55% to 62% of patients at each interval had
measurements available on sac size. Makaroun and col- aeagues reported a 2.9% rate of sac enlargement at 2 years
ith the low-porosity TAG graft, but there have been no
-year data published for this device.9 Fattori et al reported
17.1% rate of sac expansion with the Talent device over a
ean follow-up period of 24 months.15 These are data
rom a 7-center European registry over 8 years and are
ore consistent with our findings. Interestingly, 30% of
atients in this registry had no recorded data for change in
neurysm dimensions during follow-up. Sac enlargement
as noted in only two patients in long-term data with the
X2 graft, but this was a single-center experience with a
ean follow-up time of 36 months (only 18 patients at
-year follow-up interval).18
Type I and type III endoleaks continued to occur over
ach time interval of the study period (Table III) and were
he indication for the majority of secondary interventions
erformed. The Talent stent graft used in the VALOR trial
ad an early generation delivery system and surgeon expe-
ience with the technology at the time was limited. Accu-
acy of device deployment and landing in the desired prox-
mal and distal seal zones were likely to have been negatively
mpacted by these factors. Anatomic characteristics that
ake obtaining a proximal seal more difficult, such as aortic
rch angulation, were not measured in this trial. As noted in
he pivotal results for the VALOR trial,5 there were no
isaligned deployments wherein the proximal bare-stent
ortion of the device deploys in an asymmetric nonparallel
ashion relative to the aortic wall and is then prone to
ipping. Only short device lengths were available for the
ALOR trial as demonstrated by an average number of
mplants per patient of 2.7  1.3 (range, 1-7 devices).
hort device lengths and the need for more devices to cover
he full treatment length lead to an increase in the number
f overlapping segments, thereby increasing the chance of
unctional endoleaks. Aortic elongation, which may have
ontributed to the development of type III endoleaks over
ime, was not measured.
Long-term durability of TEVAR has been a concern
ince the inception of this technique, but stent graft tech-
ology has certainly evolved since the results with crude
rst-generation devices were reported.20,21 The data pre-
ented here demonstrate very low rates of device migration,
inking, and/or twisting with the Talent Thoracic Stent
raft. There were no observations of loss of stent graft
atency.However, continued occurrences of device-related
omplications over the 5-year follow-up period and the
ontinued need for secondary interventions (half of all
econdary endovascular interventions during the follow-up
eriod were performed between 1 and 5 years) speak to the
mportance of close patient follow-up.
ONCLUSIONS
Through 5-years of follow-up, in patients who were
andidates for open surgical repair, TEVAR using the Tal-
nt Thoracic Stent Graft System has demonstrated sus-
ained protection from ARM, aneurysm rupture, and con-
ersion to surgery. Close patient follow-up continues to be
n essential component in achieving these results.
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Principal investigator Site City Patients enrolled
Michael Tuchek, DO Loyola University Medical Center Maywood, Ill 18
Alan Matsumoto, MD University of Virginia Charlottesville, Va 16
Mark Farber, MD University of North Carolina Chapel Hill, NC 14
Christopher Kwolek, MD Massachusetts General Hospital Boston, Mass 13
Ronald Fairman, MD Hospital of the University of Pennsylvania Philadelphia, Pa 11
Tomas Martin, MD University of Florida Gainesville, Fla 11
Manish Mehta, MD Albany Medical Center Albany, NY 10
Seyed-Mojtaba Gashti, MD Union Memorial Hospital Baltimore, Md 9
Rodney White, MD Harbor UCLA Torrance, Calif 9
Edward Garrett, MD Baptist Memorial Hospital Memphis, Tenn 7
Gregorio Sicard, MD Washington University School of Medicine St Louis, Mo 7
Tom Bower, MD Mayo Clinic- Rochester Rochester, Minn 6
Neal Cayne, MD NYU Vascular Associates New York, NY 5
Jim Swischuk, MD St Francis Hospital Peoria, Ill 5
Daniel Benckart, MD Allegheny General Hospital Pittsburg, Pa 4
Michael Hallisey, MD Hartford Hospital Hartford, Conn 4
Peter Lin, MD Baylor College of Medicine Houston, Tex 4
Richard McCann, MD Duke University Medical Center Durham, NC 4
James McKinsey, MD New York Presbyterian Cornell University New York, NY 4
Christopher Zarins, MD Stanford University Stanford, Calif 4
Lowell Satler, MD Washington Hospital Center Washington, DC 3
Paul Bove, MD William Beaumont Hospital Royal Oak, Mich 2
Mark Eskandari, MD Northwestern Memorial Hospital Chicago, Ill 2
Mark Fillinger, MD Dartmouth- Hitchcock Medical Center Lebanon, NH 2
Kim Hodgson, MD Memorial Medical Center Springfield, Ill 2
Matthew Jung, MD Surgical Care Associates Louisville, Ky 2
Barry Katzen, MD Baptist Hospital of Miami Miami, Fla 2
Zvonimir Krajcer, MD St Luke’s Episcopal Hospital – Houston Houston, Tex 2
Sean Lyden, MD Cleveland Clinic Foundation – Ohio Cleveland, Ohio 2
Takao Ohki, MD Montefiore Medical Center Bronx, NY 2
Venkatesh Ramaiah, MD Arizona Heart Institute Phoenix, Ariz 2
Mark Bates, MD Charleston Area Medical Center Charleston, WV 1
Marc Glickman, MD Sentara Norfolk General, Vascular, and Transplant Specialists Norfolk, Va 1
Marc Kaye, MD Physician’s Regional Medical Center Naples, Fla 1
Robert Rhee, MD Shadyside Hospital – UPMC Pittsburgh, Pa 1
Timothy Roush, MD Carolinas Medical Center Charlotte, NC 1
Cary Stowe, MD Florida Hospital Orlando, Fla 1
David Williams, MD University of Michigan Ann Arbor, Mich 1VALOR, Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms.
